Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers

Harshal Surendra Mandavdhare; Vishal Sharma; Kaushal K Prasad; Amit Kumar; Manish Rathi; Surinder S Rana

doi:10.5217/ir.2017.15.3.419

Articles

Page Path: HOME > Intest Res > Volume 15(3); 2017 > Article

Case Report Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers: Harshal Surendra Mandavdhare¹, Vishal Sharma¹, Kaushal K Prasad¹, Amit Kumar¹, Manish Rathi², Surinder S Rana¹; Intestinal Research 2017;15(3):419-421.
DOI: https://doi.org/10.5217/ir.2017.15.3.419
Published online: June 12, 2017

¹Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

²Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Correspondence to Vishal Sharma, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. Tel: +91-708-7008099, Fax: +91-172-2744401, docvishalsharma@gmail.com

• Received: August 22, 2016 • Revised: September 23, 2016 • Accepted: October 4, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

5,849 Views
89 Download
14 Web of Science
13 Crossref
15 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
CASE REPORT
DISCUSSION
NOTES
REFERENCES

Abstract

Recent studies have identified sprue-like illness associated with the use of the antihypertensive agent olmesartan medoxomil. However, whether this condition is specific to the use of olmesartan or is associated with the use of drugs belonging to the class of “sartans” remains to be clarified. A 45-year-old woman with chronic kidney disease along with hypothyroidism and hypertension presented with chronic diarrhea and significant weight loss. Endoscopy of the upper gastrointestinal tract showed scalloping and grooving of the duodenum, and histopathological examination showed subtotal villous atrophy. She was on telmisartan for hypertension, which was discontinued. Subsequently, diarrhea ameliorated dramatically, and she regained weight. To our knowledge, this is the first study to report telmisartan-associated sprue-like enteropathy. Further, we have reviewed the cases of patients with sprue-like enteropathy caused by valsartan, irbesartan, and eprosartan.
Keywords: Celiac disease; Diarrhea; Malabsorption; Angiotensin receptor blockers

INTRODUCTION

Recent studies have shown that the angiotensin receptor blocker (ARB) olmesartan medoxomil induces a sprue-like illness characterized by diarrhea and malabsorption.1 2 3 This disease affects men and women equally, and most cases have been reported in men and women aged 60 to 80 years. The common presentation of this disease is chronic diarrhea with weight loss, and some patients present with fatigue, nausea, vomiting, abdominal pain, and bloating. Majority of the patients exhibit total or partial villous atrophy, which improves with drug withdrawal.1 Several studies have reported sprue-like enteropathy associated with olmesartan; however, only 5 cases of patients with sprue-like enteropathy associated with telmisartan, valsartan, irbesartan, and eprosartan have been reported thus far.1 4 5 6 7 8 The patient with telmisartan-induced sprue-like enteropathy exhibited ileitis with colitis without the involvement of the duodenum.4 To our knowledge, our study has reported telmisartan-induced sprue-like enteropathy involving the duodenum for the first time.

CASE REPORT

A 45-year-old woman with hypothyroidism and hypertension and a history of chronic kidney disease had presented with chronic diarrhea and weight loss of 10 kg for the past 8 months. She had anemia, and her hemoglobin level was 10.3 g/dL; total leukocyte count was 7,600×10³/dL; and platelet count was 2.34×10³/dL. She also exhibited impaired renal function with BUN and creatinine levels of 67 mg/dL and 2.1 mg/dL, respectively. She had hypoalbuminemia with an albumin level of 2.7 g/dL. The results of the liver function test were normal, and her total bilirubin level was 0.9 mg/dL; direct bilirubin level was 0.2 mg/dL; aspartate transaminase level was 26 IU/L; alanine transaminase level was 20 IU/L; and ALP level was 117 IU/L. Electrocardiograph showed left ventricular hypertrophy, and the chest radiograph showed no abnormalities. To determine the cause of diarrhea, we performed the routine stool examination and culture, which were noncontributory. Further, the results of serological examination for celiac disease (IgA anti-tissue transglutaminase antibody) were negative. Her upper gastrointestinal endoscopy revealed typical scalloping and grooving with nodularity (Fig. 1). Multiple samples were taken from the second part of the duodenum and biopsy was performed, which showed subtotal atrophy of the duodenal villous pattern (Fig. 2). The patient had been prescribed telmisartan 40 mg daily for hypertension for the past 1 year. After discontinuation of telmisartan and switching to amlodipine, diarrhea subsided, renal function improved, and significant weight gain was observed. Follow-up endoscopy showed normal duodenal folds 4 months after discontinuation of telmisartan.

DISCUSSION

Several recent studies have reported olmesartan-induced sprue-like enteropathy.1 2 3 4 A systematic review of 54 cases of olmesartan-induced sprue-like enteropathy showed that 64% patients were human leukocyte antigen (HLA) DQ2/DQ8 positive, whereas the incidence of HLA DQ2/DQ8-positive individuals is 40% among the general population; therefore, the involvement of the HLA system in this disease cannot be ruled out.3 Interestingly, similar to patients with celiac sprue, some patients with sprue-like enteropathy show a subepithelial collagen band, with one-third having lymphocytic gastritis.2 3

The pathogenesis underlying this condition is unclear; however, it is believed that angiotensin II plays a proapoptotic role by acting on angiotensin (AT) 2 receptors in the proximal gut because of selective saturation of AT 1 receptors by sartans; further, impaired interleukin-15 signaling and disruption of the tight junction protein zonula occludens-1 has been implicated in this condition.9 10

A recent study reported the case of a patient with telmisartan-induced collagenous ileitis, colitis, and gastritis; however, this patient showed normal pattern of the duodenal villi on endoscopy of the upper gastrointestinal tract, and biopsy of the duodenum showed no abnormalities.4 A previous study has shown sprue-like enteropathy associated with irbesartan and valsartan.1

To our knowledge, this is the first study to report on the association between telmisartan and sprue-like enteropathy involving the duodenum. The cases of patients with spruelike enteropathy caused by ARBs belonging to the sartan class other than olmesartan are shown in Table 1.4 5 6 7 8 Our results indicate that sprue-like enteropathy is associated with the sartan class of ARBs rather than a single drug. Therefore, the possibility of sprue-like enteropathy should be considered as a differential diagnosis in patients who receive antihypertensives belonging to the sartan class, develop new-onset diarrhea, undergo weight loss, or show features of malabsorption.

NOTES

Financial support: None.

Conflict of interest: None.

REFERENCES

1. Choi EY, McKenna BJ. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch Pathol Lab Med 2015;139:1242–1247.PMID: 26414468.Article PubMed
2. Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol 2016;50:127–134.PMID: 26997446.Article PubMed
3. Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014;40:16–23.PMID: 24805127.Article PubMed
4. Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy: is there any class effect? Aliment Pharmacol Ther 2014;40:569–570.PMID: 25103353.Article PubMed
5. Cammarota G, Ianiro G, Bibbò S, Gasbarrini A. Letter: telmisartan associated enteropathy: is there any class effect? Authors' reply. Aliment Pharmacol Ther 2014;40:570PMID: 25103354.Article PubMed
6. Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther 2014;40:1103–1109.PMID: 25199794.Article PubMed
7. Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J 2015;2:92–94.PMID: 26157924.Article PubMed PMC
8. Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol 2015;51:87–88.PMID: 25970720.PubMed
9. Sun L, Wang W, Xiao W, Liang H, Yang Y, Yang H. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA-6 and the Bax pathway. Biochem Biophys Res Commun 2012;424:663–668.PMID: 22776205.Article PubMed
10. Marietta EV, Nadeau AM, Cartee AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther 2015;42:1303–1314.PMID: 26423313.Article PubMed PMC

Fig. 1

Mucosa of the duodenum showing grooving and scalloping.

Fig. 2

Subtotal villous atrophy with increased numbers of intraepithelial lymphocytes and crypt hyperplasia (H&E, ×200).

Table 1

Report of Non-olmesartan Angiotensin Receptor Blocker-Related Cases of Sprue-Like Enteropathy

Case	Age (yr)	Sex	Causing drug	Duration of drug use	Involved organ	Pathologic findings	Clinical outcome
Case 14	71	Female	Telmisartan	2 mo	Colon, ileum, and stomach	Severe villous atrophy, intraepithelial lymphocytosis, subepithelial collagen band in terminal ileum, colonic, and stomach biopsies	Symptoms and histology improved in 7 mo of stopping the drug
Case 27	80	Female	Irbesartan	6 mo	Duodenum	Total atrophy of villous pattern	Improved clinically and histologically within 3 mo
Case 38	54	Female	Irbesartan	9 mo	Duodenum	Total villous atrophy	Clinical improvement after stopping the drug
Case 49	71	Female	Valsartan	5 yr	Duodenum and jejunum	Complete villous atrophy, intraepithelial lymphocytosis, and crypt hyperplasia	Improved after stopping the drug
Case 510	83	Female	Eprosartan	10 yr	Duodenum	Flattened mucosa and increase in ntraepithelial lymphocytesand	Improved
Present case	45	Female	Telmisartan	1 yr	Duodenum	Subtotal atrophy of the duodenal villous pattern	Clinical and histological improvement

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Olmesartan induced gastritis and enteropathy
Ankur Gupta, Priyanka Jain, Latika Gupta
Indian Journal of Gastroenterology.2024; 43(3): 684. CrossRef
Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers
Annalisa Schiepatti, Paolo Minerba, Michele Puricelli, Stiliano Maimaris, Giovanni Arpa, Federico Biagi, David S. Sanders
Alimentary Pharmacology & Therapeutics.2024; 59(4): 432. CrossRef
Olmesartan induced enteropathy affecting the entire gastrointestinal tract: a case report
N Van Horebeek, R Croes, A Vonck, E Colpaert
Acta Gastro Enterologica Belgica.2023; 86(1): 95. CrossRef
A Case of Sprue-like Enteropathy Associated With Valsartan and Irbesartan
Seo Yeon Yoo, Jihun Kim, Kee Wook Jung
Journal of Neurogastroenterology and Motility.2022; 28(2): 327. CrossRef
The histological spectrum of ARB‐induced gastritis
Tanner Storozuk, Ian Brown, Stephen Lagana, Maria Westerhoff, Namrata Setia, John Hart, Lindsay Alpert
Histopathology.2022; 81(5): 653. CrossRef
Severe cases of sprue‐like enteropathy associated with angiotensin receptor blockers other than olmesartan
Peter Malfertheiner, Chiara Formigoni
GastroHep.2021; 3(2): 88. CrossRef
Telmisartan-induced sprue-like enteropathy: a case report
Natalia Alzueta, Amaya Echeverría, Lorea Sanz, Carmen Fontela, Teresa Acín, Lidia Montenegro, Javier Garjón
European Journal of Hospital Pharmacy.2020; 27(1): 49. CrossRef
Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture
Francesco Abbruzzi, Ilaria Loconte, Sonia Carparelli, Enzo Ierardi, Alfredo Di Leo, Mariabeatrice Principi
Current Drug Safety.2020; 15(1): 65. CrossRef
Traitement par olmésartan et entéropathie : à propos de deux cas et revue de la littérature
A. Sadki, M. Le Besnerais, F. Héron, I. Marie
La Revue de Médecine Interne.2019; 40(2): 112. CrossRef
A simple treatment for a potentially life-threatening cause of malabsorption
Mattia Bonzi, Elisa M. Fiorelli, Gaia Montanelli, Ludovico Furlan, Monica Solbiati
Internal and Emergency Medicine.2019; 14(6): 967. CrossRef
Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review
Ayesha Kamal, Christopher Fain, Angela Park, Peiqi Wang, Eduardo Gonzalez-Velez, Daniel A Leffler, Susan M Hutfless
Gastroenterology Report.2019; 7(3): 162. CrossRef
Association of sprue-like enteropathy and angiotensin receptor-1 antagonists
René R. Wenzel, Christian Datz
Wiener klinische Wochenschrift.2019; 131(19-20): 493. CrossRef
Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy
Peter Malfertheiner, Claudio Ripellino, Nazarena Cataldo
Pharmacoepidemiology and Drug Safety.2018; 27(6): 581. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers

Intest Res. 2017;15(3):419-421. Published online June 12, 2017

DOI: https://doi.org/10.5217/ir.2017.15.3.419

XML Download

Figure

Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers

Fig. 1 Mucosa of the duodenum showing grooving and scalloping.

Fig. 2 Subtotal villous atrophy with increased numbers of intraepithelial lymphocytes and crypt hyperplasia (H&E, ×200).

Fig. 1

Fig. 2

Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers

Table 1

Report of Non-olmesartan Angiotensin Receptor Blocker-Related Cases of Sprue-Like Enteropathy

Case	Age (yr)	Sex	Causing drug	Duration of drug use	Involved organ	Pathologic findings	Clinical outcome
Case 14	71	Female	Telmisartan	2 mo	Colon, ileum, and stomach	Severe villous atrophy, intraepithelial lymphocytosis, subepithelial collagen band in terminal ileum, colonic, and stomach biopsies	Symptoms and histology improved in 7 mo of stopping the drug
Case 27	80	Female	Irbesartan	6 mo	Duodenum	Total atrophy of villous pattern	Improved clinically and histologically within 3 mo
Case 38	54	Female	Irbesartan	9 mo	Duodenum	Total villous atrophy	Clinical improvement after stopping the drug
Case 49	71	Female	Valsartan	5 yr	Duodenum and jejunum	Complete villous atrophy, intraepithelial lymphocytosis, and crypt hyperplasia	Improved after stopping the drug
Case 510	83	Female	Eprosartan	10 yr	Duodenum	Flattened mucosa and increase in ntraepithelial lymphocytesand	Improved
Present case	45	Female	Telmisartan	1 yr	Duodenum	Subtotal atrophy of the duodenal villous pattern	Clinical and histological improvement

Table 1 Report of Non-olmesartan Angiotensin Receptor Blocker-Related Cases of Sprue-Like Enteropathy